Cook first to file paclitaxel-eluting stent:
This article was originally published in Clinica
Executive Summary
Cook has become the first company to submit a marketing application for a paclitaxel-eluting coronary stent anywhere in the world, after filing the device for European CE mark approval. The filing was based on the results of Cook's European-based ELUTES clinical trial, which revealed a binary restenosis rate of just 3.1% due to paclitaxel's cytostatic mechanism of action in inhibiting neointimal hyperplasia. "Cook could begin selling its first drug-eluting coronary stents in Europe during the second quarter of this year," predicted Kem Hawkins, the Bloomington, Indiana firm's president.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.